In contrast, quantitative IHC analysis of tumor tissues from cancer patients shows that anti-CTLA-4 immunotherapy using ipilimumab or tremelimumab (anti-human CTLA-4 hIgG2) did not deplete Foxp3+cells in human tumors [17]. This evidence concerns the gene CTLA4 and cancer.